Edwards Lifesciences Corp (EW)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 3,045,200 | 3,676,400 | 1,648,000 | 1,224,600 | 1,144,000 | 1,410,100 | 1,042,600 | 872,500 | 769,000 | 1,247,800 | 1,198,100 | 1,030,900 | 862,800 | 1,506,900 | 1,312,800 | 1,174,200 | 1,183,200 | 1,024,000 | 903,500 | 662,900 |
| Short-term investments | US$ in thousands | 930,700 | 769,700 | 345,300 | 473,000 | 500,500 | 453,800 | 466,700 | 381,700 | 446,300 | 490,900 | 317,700 | 465,000 | 604,000 | 287,800 | 248,400 | 156,400 | 219,400 | 271,300 | 260,300 | 368,200 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 1,505,200 | 1,944,100 | 1,217,000 | 1,110,800 | 1,195,400 | 1,238,900 | 1,157,200 | 1,082,000 | 1,022,400 | 917,900 | 969,100 | 949,900 | 1,032,300 | 966,500 | 886,200 | 799,000 | 893,900 | 846,300 | 873,200 | 746,900 |
| Quick ratio | 2.64 | 2.29 | 1.64 | 1.53 | 1.38 | 1.50 | 1.30 | 1.16 | 1.19 | 1.89 | 1.56 | 1.57 | 1.42 | 1.86 | 1.76 | 1.67 | 1.57 | 1.53 | 1.33 | 1.38 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($3,045,200K
+ $930,700K
+ $—K)
÷ $1,505,200K
= 2.64
The quick ratio of Edwards Lifesciences Corp has shown fluctuations over the years, ranging from a low of 1.16 as of March 31, 2023, to a high of 2.64 as of December 31, 2024. The quick ratio measures the company's ability to meet its short-term obligations using its most liquid assets, excluding inventory. A quick ratio above 1 indicates that the company has an adequate level of liquid assets to cover its short-term liabilities.
The quick ratio increased consistently from December 31, 2021, to September 30, 2022, reaching a peak of 1.89 before decreasing slightly in the following periods. This suggests that the company was able to improve its liquidity position during this time frame. However, there was a significant increase in the quick ratio from September 30, 2024, onwards, reaching 2.64 by December 31, 2024. This substantial increase indicates that the company significantly improved its ability to cover its short-term obligations with liquid assets.
Overall, the trend in Edwards Lifesciences Corp's quick ratio indicates a general improvement in the company's liquidity position over the analyzed periods, with periodic fluctuations that should be further investigated to understand the company's changing financial dynamics.
Peer comparison
Dec 31, 2024